Global Antibody Partnering Terms and Agreements Directory 2010-2018 - ResearchAndMarkets.com

DUBLIN--()--The "Global Antibody Partnering Terms and Agreements 2010-2018: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

The Global Antibody Partnering Terms and Agreements 2010 to 2018 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report contains over 1,200 links to online copies of actual Antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

  • Antibodies
  • Antibody-drug conjugates
  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb
  • Polyclonal Antibodies

Report scope

Global Antibody Partnering Terms and Agreements 2010 to 2018 includes:

  • Trends in Antibody dealmaking in the biopharma industry since 2010
  • Analysis of Antibody deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Antibody deals
  • Access to over 1,200 Antibody online deal records
  • The leading Antibody deals by value since 2010
  • Most active Antibody dealmakers since 2010
  • The leading Antibody partnering resources

In Global Antibody Partnering Terms and Agreements 2010 to 2018, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

Chapter 3 - Leading antibody deals

Chapter 4 - Most active antibody dealmakers

Chapter 5 - Antibody contracts dealmaking directory

Chapter 6 - Antibody dealmaking by technology type

Chapter 7 - Partnering resource center

Appendices

Appendix 1 - Antibody deals by company A-Z

Appendix 2 - Antibody deals by stage of development

Appendix 3 - Antibody deals by deal type

Appendix 4 - Antibody deals by therapy area

Appendix 5 - Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/research/fn7npb/global_antibody?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs